American Journal of Respiratory and Critical Care Medicine

Randomized, controlled trials have demonstrated that chronic therapy with macrolide antibiotics reduces the morbidity of patients with cystic fibrosis, non–cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, and nontuberculous mycobacterial infections. Lower levels of evidence indicate that chronic macrolides are also effective in treating patients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung transplant. Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, and a recent observational study prompted the FDA to strengthen the Warnings and Precautions section of azithromycin drug labels. This summary describes the electrophysiological effects of macrolides, reviews literature indicating that the large majority of subjects experiencing cardiac arrhythmias from macrolides have coexisting risk factors and that the incidence of arrhythmias in absence of coexisting risk factors is very low, examines recently published studies describing the relative risk of arrhythmias from macrolides, and concludes that this risk has been overestimated and suggests an approach to patient evaluation that should reduce the relative risk and the incidence of arrhythmias to the point that chronic macrolides can be used safely in the majority of subjects for whom they are recommended.

Pulmonary physicians frequently encounter patients for whom chronic macrolide therapy should be considered based on the results of high-quality randomized trials (i.e., cystic fibrosis, non–cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease [COPD] and nontuberculous mycobacterial infections). Lower levels of evidence suggest that chronic macrolides are also effective in treating subjects with panbronchiolitis and those with bronchiolitis obliterans and rejection after lung transplantation.

In response to a recently published observational study (1), the FDA warned that azithromycin can change the electrical activity of the heart and reiterated a 2011 product label revision stating that patients with risk factors were at particular risk and strengthened the Warnings and Precautions section of azithromycin drug labels. Accordingly, physicians have to weigh the relative risk (RR) of arrhythmias developing versus the reduction in morbidity that could be achieved by prescribing chronic macrolides.

This review describes the electrophysiological effects of macrolides, explains the genetic mechanisms of these effects, summarizes the importance of coexisting risk factors in the development of arrhythmias, critically reviews recently published studies estimating the increased RR of macrolide-associated arrhythmias, and suggests an approach by which these risks can be reduced.

The QT interval of the electrocardiogram (ECG) varies from beat-to-beat, from day-to-day, and diurnally and is affected by numerous factors, including gender, age, autonomic tone, and heart rate (Table 1). The QT interval is expressed as the QTc interval after adjusting for heart rate using any of several of correction formulas. QT prolongation itself does not adversely affect cardiac function (2), but prolongation portends the possibility of more serious arrhythmias.

Table 1: Factors Prolonging the QT Interval and Possibly or Probably Increasing the Risk of Cardiac Arrhythmias Developing after Macrolide Administration

Risk Factor CategoryExamples
GeneticLong QT syndrome
 Unidentified channelopathies
 Female gender
Underlying cardiac diseaseBradycardia
 Congestive heart failure
 Baseline QT prolongation
 Myocardial ischemia and infarction
 Atrial fibrillation
Metabolic abnormalitiesHypokalemia
 Acute hypercarbia and/or hypoxia
Taking other medications with risk of QT prolongation without dose adjustment when metabolism or clearance of these medications is impairedRenal or hepatic insufficiency
 Genetic polymorphisms
 Concurrent cytochrome P450 inhibitors
Administration of multiple drugs with QT liabilityAs summarized in Reference 8

Summary of References 6, 7, and 65 with additions.

Normal values for the QT interval and the RR of torsade des pointes (TdP) have been estimated from population-based studies (Table 2) (3). Roden (4) suggested that QT prolongation beyond 500 milliseconds, or by >50 milliseconds from the baseline, as a result of a medication should prompt a search for potential predisposing or contributing factors, and if these cannot be identified and corrected the benefit of continuing the associated medication should be reconsidered. Several groups, however, suggest that QT prolongation is an insensitive and nonspecific predictor of adverse cardiac events because the majority of patients with medication-induced QT prolongation do not develop TdP, and many patients who develop TdP have a normal QT interval (57).

Table 2: QT Interval Prolongation and Risk of Sudden Cardiac Death in Patients > 55 yr of Age

 Male PatientsFemale Patients
QT Interval (ms)Hazard Ratio for Sudden Cardiac DeathQT Interval (ms)Hazard Ratio for Sudden Cardiac Death

Data from Reference 3.

A list of medications that prolong the QT interval and cause TdP, categorized into four groups of presumed risk, is available on the internet (8). Erythromycin, azithromycin, and clarithromycin are all listed in risk category 1 (“Substantial evidence… that these drugs…can prolong the QT interval and can have a risk of torsades de pointes”). Forty-one other medications are included in this category, including haloperidol and droperidol, ondansetron, moxifloxacin, and methadone.

In their resting state, cardiac myocytes have a transmembrane electrical potential of approximately −90 mV. When the cells depolarize (represented by the QRS complex), the potential increases to approximately +20 mV. Repolarization (represented by the T wave and the QT interval) occurs in three phases. The early repolarization and plateau phases (phase 1 and 2, respectively) are largely the result of potassium and calcium currents. Phase 3 repolarization occurs when potassium channels open and the cell returns to its resting negative state (phase 4). QT prolongation can result in early after-depolarizations (EADs) in the third phase. If EADs reach the threshold electrical potential, they can induce TdP, which can result in ventricular fibrillation. Accumulation of potassium within the myocytes delays repolarization. The rapidly activating delayed rectifier potassium channel (IKr) controls movement of potassium out of the myocyte, is responsible for phase 3 repolarization, is encoded by the human ether-a-go-go-related gene (hERG), and is affected by macrolides and many other medications in a concentration-dependent fashion (912).

Mutations in hERG are responsible for the congenital Type 2 Long QT syndrome and for the prolonged QT intervals acquired as a result of Type Ia and Type III antiarrhythmic agents. Almost all medications that prolong the QT interval and cause TdP block IKr, but many medications that do not cause TdP also block IKr (e.g., verapamil and amiodarone) (7, 13). The observation that not all patients prolong their QT interval after taking macrolides and that even fewer patients experience potentially lethal arrhythmias suggests that additional patient-specific variables are important (see below).

From 5 to 20% of patients who develop TdP after taking QT-prolonging medications have subclinical congenital QT prolongation. Incomplete penetrance of hERG mutations may be present despite near-normal QT intervals, representing a second mechanism by which macrolides may prolong the QT interval (1418). In addition, several IKr-specific genes have been identified that do not independently cause QT prolongation but that block IKr, prolong the QT interval, and cause TdP in the presence of medications (5, 14, 1923).

The effect of macrolides on repolarization is only observed in the His-Purkinje tissue and the M cells in the ventricular myocardium (i.e., there is little or no drug effect in the endocardium and epicardium). This disparity leads to dispersion of repolarization across the myocardium, a third mechanism by which the risk of arrhythmias and TdP can develop.

The QT interval before receiving an at-risk medication is longer in patients who develop TdP after receiving the medication than in those who do not (2325). This observation led to the concept of “repolarization reserve” (23), suggesting that anything that impairs repolarization (as summarized in Table 1) makes TdP more likely when an IKr-blocking medication is prescribed.

Ponsonnaille and colleagues (26) first assessed the electrophysiological effects of intravenous erythromycin and found that the effect on the QTc interval was directly related to the rate of infusion because the QTc interval increased an average of 42 and 33 milliseconds in subjects who received a 500-mg dose of the medication over 1 or 20 minutes, respectively. Atrial and ventricular refractory periods were also prolonged by the rapid, but not the slower, infusion. Similar results were reported by others (27, 28).

In vitro studies find no effect of erythromycin on repolarization at a concentration of 10 mg/L (29), prolonged repolarization at 20 to 50 mg/L, further prolongation at 100 mg/L, and EADs at 50 to 200 mg/L (911, 29). Intravenous administration of erythromycin (500 mg) over 15 minutes produces peak serum concentrations of approximately 45 mg/L 3 minutes after the injection (30). Slower administration produces lower levels (31), whereas oral administration results in a peak concentration of ∼2 to 4 mg/L (32). Accordingly, arrhythmias should not occur after oral dosing in the absence of other confounding issues.

Azithromycin may be the macrolide that is least likely to cause cardiac arrhythmias. Ohtani and colleagues (33) found the rank order of concentration-dependent QT prolongation in rats was erythromycin > clarithromycin > roxithromycin > azithromycin. Milberg and colleagues (34) found that erythromycin, clarithromycin, and azithromycin all prolonged the QT interval, but after decreasing potassium concentrations erythromycin and clarithromycin led to EADs and TdP, whereas azithromycin did not.

The patients who are described in the literature as developing arrhythmias after receiving macrolide antibiotics have a strikingly high prevalence of other factors that could cause or contribute to the arrhythmias.


Of the first 13 reports of patients with arrhythmias occurring in conjunction with erythromycin (all after intravenous administration), 12 had one or more the conditions summarized in Table 1, and 4 or 5 of 11 reports with sufficient information to assess had acute hypoxemia or hypercarbia (3545). The only patient with no apparent risk factors was an 8-day-old baby who received multiple intravenous injections of the macrolide. Bandriss and colleagues (46) concluded that intravenous erythromycin could induce TdP when given alone but that TdP occurred more commonly when the QTc interval was prolonged by other conditions.

Tschida and colleagues (47) performed a comprehensive review of 23 patients described in 17 case reports in which TdP and/or ventricular tachycardia were reported in association with erythromycin. Fourteen (61%) had known cardiac disease. Of the nine subjects without cardiac disease, five received the erythromycin as a rapid intravenous bolus, two were receiving other medications known to prolong repolarization, and one had active liver disease.

The first report of oral erythromycin causing arrhythmias was in a patient with congenital long QT syndrome (38). The next report occurred in a patient who was also taking disopyramide, a class Ia antiarrhythmic that prolongs the QT interval (48), and the third was in a patient with sinus bradycardia who received 4 g of erythromycin orally over 6 hours for a preoperative bowel preparation and became symptomatic directly after intravenous administration of ranitidine (49).


The first case report of arrhythmias developing after clarithromycin was in a patient with pulmonary hypertension, cor pulmonale, hypoalbuminemia, and transaminitis, and the second was in a patient with hepatitic C and heart failure who was on dialysis (50). The next four reports occurred in patients who were taking multiple QT-prolonging medications (one of whom also had hypokalemia) or had congenital QT prolongation (5153).


In 2013, over 57 million outpatient prescriptions were written for macrolide antibiotics in the United States, and 51.5 million of these (90%) were for azithromycin (54). The first patient reported to have arrhythmias in association with azithromycin was also receiving disopyramide (55). The second patient had congenital long QT syndrome, and the third, fourth, and fifth all had congestive heart failure (5659). Kim and colleagues (60) and Kezerashvili and colleagues (61) published what they believed to be the first reports of TdP occurring in patients with no apparent predisposing comorbidities, but the first of these patients had taken pseudoephedrine in conjunction with the azithromycin and also had hypokalemia, and the second had a pacemaker for intermittent symptomatic bradycardia, had developed acute renal failure requiring dialysis, and was taking moxifloxacin and ciprofloxacin at the time the TdP was observed.

Raschi and colleagues (62) investigated cases of drug-induced arrhythmias submitted to the FDA Adverse Event Reporting System from 2004 through 2011. Over the 8-year study period, only 63 and 84 cases of TdP or QT prolongation, respectively, were reported in association with macrolides, and 59 and 45% of these, respectively, occurred in conjunction with the subjects taking other medications known to have a definite or probable risk of causing QT prolongation.

Justo and Zeltser (63) examined subjects reported in Pubmed citations to 2005 and identified by direct inquiry of pharmaceutical companies and found 78 patients who developed TdP. Macrolides were considered to be responsible for 50 (64%) of these cases, and 37 (74%) patients had two or more risk factors for TdP that could be determined from the subjects' history or ECG.

Ray and colleagues (64) reported that the RR of sudden death from cardiac causes was higher in patients currently using erythromycin compared with subjects who were taking no antibiotics (Table 3). The effect of taking CYP3A inhibitors was striking in this study. Subjects taking erythromycin in addition to CYP3A inhibitors had a 3-fold greater incidence of sudden cardiac death than those taking erythromycin alone, and the incidence of sudden cardiac death in subjects taking erythromycin without CYP3A inhibitors was within the 95% confidence interval (CI) of the incidence in subjects taking amoxicillin alone (Table 3).

Table 3: Incidence of Sudden Cardiac Death in Subjects Taking Oral Antibiotics with or without CYP3A Inhibitors

Medication(s)DeathsPerson-Years of Follow-upIncidence Ratio (95% CI)
Erythromycin with or without CYP3A inhibitor105,30520.1 (1.08–3.75)
Amoxicillin with or without CYP3A inhibitors86,8461.18 (0.59–2.36)
No antibiotic with or without CYP3A inhibitors1,3581,126,0131.00
Erythromycin with CYP3A inhibitor31945.35 (1.72–16.64)
Erythromycin without CYP3A inhibitor74,8741.79 (0.85–3.76)
Amoxicillin with CYP3A inhibitor02540
Amoxicillin without CYP3A inhibitor86,3041.48 (0.74–2.97)
No antibiotic with CYP3A inhibitors11636,5180.93 (0.76–1.13)
No antibiotic without CYP3A inhibitors1,2351,163,0871.00

Definition of abbreviation: CI = confidence interval.

Data from Reference 64.

In sum, it is difficult to find reports of patients experiencing arrhythmias in response to macrolides who do not have one or more additional risk factors for developing arrhythmias. Mosholder and colleagues (65) concluded that having a risk factor for QT prolongation increases the likelihood of azithromycin-associated cardiovascular death by more than 24-fold.

In 2001, the FDA Pink Sheet reported 10 cases of QTc-related cardiac events out of 10 million prescriptions of azithromycin (66).

The article resulting in the reemergence of concern for macrolide-associated arrhythmias was published by Ray and colleagues (1). They examined 14 years of data collected from a Medicaid database in Tennessee and found an increased risk of cardiovascular deaths and death from any cause during the first 5 days after patients were prescribed azithromycin compared with when they were prescribed no antibiotics or amoxicillin (Table 4). Several issues complicate interpretation of their data.

Table 4: Summary of the Results of Ray and Colleagues (1)

VariableNo AntibioticsAmoxicillinAzithromycin
Treatment courses1,391,1801,348,672347,795
Cardiovascular deaths414229
Cardiovascular deaths/million courses29.831.585.2
 HR (95% CI)10.95 (0.55–1.63)2.88 (1.79–4.63)
P value 0.85<0.001
Sudden cardiac death332922
Sudden cardiac deaths/million courses24.021.864.6
 HR (95% CI)10.85 (0.45–1.60)2.71 (1.58–4.64)
P value 0.62<0.001

Definition of abbreviations: CI = confidence interval; HR = hazard ratio.

First, the paper focused on the RR of arrhythmias and did not present the number of patients included in the three treatment groups. Accordingly, the incidence of arrhythmias could not be determined. Based on the data provided, the incidence could vary at least 10-fold.

Second, because of the large number of antibiotic courses studied, the low number of deaths observed (i.e., 29 in the azithromycin arm over 14 yr), and the observational design of the study, even small differences in any of numerous comorbidities could account for some or all of the difference in the RRs of cardiovascular deaths reported. For example, current or past use of antipsychotic medications was reported in 11.5% of the patients during periods when they were receiving no antibiotics and in 11.8% of the patients during periods when azithromycin was taken. Given the large number of periods studied, this 0.3% difference could equate to as many as 1,043 more courses of azithromycin being taken while patients were receiving antipsychotics. If even a few of the deaths observed in the azithromycin arm were the result of concurrent antipsychotic use, it could alter the RRs reported for azithromycin to a considerable extent. A similar concern would pertain to many other medications that could contribute to QT prolongation.

Third, the history obtained regarding other medications grouped the responses as “current or past use.” This blurs the matching process because the effect that other medications might have on the development of arrhythmias obviously depends on whether these medication were being taken at the time the patient was assessed. In reviewing the results of this study, Mosholder and colleagues (65) pointed out that it was not possible to know for certain whether the propensity scores successfully adjusted the data.

Fourth, women made up 78% of the cohort. QTc intervals are longer and TdP occurs more commonly in women than in men, possibly because of the effects of sex hormones on myocardial tissue (6774). Lehmann and colleagues (74) suggest that TdP occurs three times more commonly in women than in men. Using the FDA Medwatch data, Drici and colleagues (69) found that 67% of the macrolide-related deaths occurred in women despite there being no gender differences in prescribing patterns. If both of these estimates are correct, Ray and colleagues (1) could have overestimated the RR of azithromycin causing cardiac deaths by nearly 30% because of the imbalance of women in the cohort.

Fifth, the increased risk of cardiovascular deaths observed with azithromycin in comparison to periods when no antibiotics were taken could have resulted from the adverse effects of the infection for which the antibiotic was prescribed (i.e., confounding by indication) rather than to azithromycin-induced arrhythmias per se. Ray and colleagues (1) address this limitation by reporting no increase in deaths during periods when patients took amoxicillin compared with when no antibiotics were being taken (Table 4). Although patients who took azithromycin were carefully matched with those taking no antibiotics, no matching was done for those taking amoxicillin “because matching would have substantially decreased the sample size” (1). Compared with patients receiving no antibiotics, those receiving azithromycin were nearly identically matched with respect to nearly every variable assessed, but a lower percentage of those receiving amoxicillin were taking every medication recorded with the exceptions of digoxin and insulin (and with strikingly lower use of statins and β agonists), and the amoxicillin group had a lower prevalence of every major comorbid condition recorded (including heart failure) and fewer hospital and urgent care visits. Accordingly, fewer deaths could have occurred in those receiving amoxicillin because they were healthier than those receiving no antibiotics.

Because of the high prevalence of coexisting conditions and the high mortality in the cohort reported by Ray and colleagues (1), Svanstrom and colleagues (75) asked whether the increased risks of cardiovascular death with azithromycin would generalize to patients seen in routine clinical practice. In their study, the number of cardiovascular deaths within the first 5 days of receiving a prescription for azithromycin was small but greater than what was observed in subjects with no antibiotic use (17/1,102,050 prescriptions of azithromycin vs. 6/1,102,050 episodes of no antibiotics [RR, 2.85; 95% CI, 1.13–7.24) but was the same as that seen within 5 days of receiving a prescription for penicillin V (RR, 0.93; 95% CI, 0.56–1.55). They interpreted their data as indicating that the increased death rate observed with azithromycin relative to no antibiotic use “was entirely attributable to the risk of death associated with acute infection…rather than with its treatment.” Svanstrom and colleagues (75) found a cardiovascular mortality of 5.4 deaths/million periods of observation when no antibiotics were being taken, compared with 29.8/million periods of observation reported by Ray and colleagues (1). Although the 5.5-fold difference suggests that there were major differences in the cohorts studied, an additional explanation could be the widely recognized limitations of observational studies (76).

Two studies have reported that treatment with macrolides was associated with an increased risk of cardiovascular events occurring well beyond the period when the macrolide was taken (77, 78). Both studies were designed to test the hypothesis that macrolides decreased the inflammation associated with cardiovascular disease, thereby decreasing adverse cardiac events. In the first study, Jespersen and colleagues (77) studied the effect of 2 weeks of clarithromycin (500 mg daily) versus placebo in 4,373 patients with stable coronary artery disease. No difference between the two groups was seen with respect to the primary outcome (i.e., composite of all-cause mortality, myocardial infarction, or unstable angina at 3 yr) or secondary outcome (i.e., composite of cardiovascular mortality myocardial infarction or unstable angina at 3 yr), and none of the prespecified outcomes was significantly different by multivariate analysis. However, when the primary and secondary endpoints were analyzed separately (which the authors identified as being tertiary outcomes), all-cause mortality was higher in the subjects receiving clarithromycin as a result of cardiovascular mortality. Jespersen and colleagues (77) pointed out two potential weaknesses in their study: (1) the study groups might not have been balanced with respect to cardiac function because they had no information pertaining to New York Heart Association class or ejection fraction at randomization, and (2) they had no knowledge of what treatments the patients in either group received during the 3-year follow-up. An additional observation from this study is that, as opposed to the striking difference in cardiovascular deaths within 5 days of starting azithromycin reported by Ray and colleagues (1), Jespersen and colleagues (77) found two early cardiovascular deaths in patients receiving clarithromycin and four in those receiving placebo.

The second study used an observational design to examine databases of 1,343 patients with COPD and 1,631 patients with community-acquired pneumonia who were hospitalized in the United Kingdom (78). Patients were considered to have used macrolides if they received at least one dose of clarithromycin during their index hospitalization, and the maximum duration of treatment studied was 14 days. During the 1-year follow-up, 268 patients with COPD and 171 patients with community-acquired pneumonia were readmitted to a hospital as a result of a cardiovascular event, with hazard ratios of cardiovascular events for those who took clarithromycin of 1.48 (95% CI, 1.13–1.94) and 1.75 (95% CI, 1.25–2.45), respectively (Table 5). Again as opposed to the findings of Ray and colleagues (1), Schembri and colleagues (78) found no increased mortality for patients taking the macrolide for the first 6 days and found no association between the risk of cardiovascular events while patients were taking the clarithromycin compared with when they were not.

Table 5: Frequency of Cardiovascular Events in Clarithromycin Users versus Nonusers

EventsCOPD CohortCAP Cohort
Use (n = 281)Nonuser (n = 1,062)User (n = 980)Nonuser (n = 651)
Myocardial infarction, n (%)12 (4.3)29 (2.7)25 (2.6)9 (1.4)
NSTEMI or ACS, n (%)14 (5.0)40 (3.8)29 (3.0)11 (1.7)
CHF or LVF, n (%)32 (11.4)56 (5.3)32 (3.3)21 (3.2)
Arrhythmia, n (%)47 (16.7)108 (10.2)64 (6.5)23 (3.5)
Cardiac arrest/sudden cardiac death, n (%)2 (0.7)3 (0.3)14 (1.4)6 (0.9)

Definition of abbreviations: ACS = acute coronary syndrome; CAP = community-acquired pneumonia; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; LVF = left ventricular failure; NSTEMI = non–ST elevation myocardial infarction.

Data from Reference 76.

The increased cardiovascular mortality seen in these two studies conflict directly with at least 11 large, randomized trials testing the same hypothesis. The randomized studied reported either no increase or reductions in cardiac deaths in patients receiving various durations of macrolides to treat the inflammation associated with vascular disease (7989).

Al-Khatib and colleagues (5) suggest that ECGs should be obtained on all patients before and after starting medications known to prolong the QT interval. Shah (2) proposes a similar approach but limits ECGs to patients with additional risks of QT prolongation.

In our recently published study of azithromycin in patients with COPD (90), we screened patients by taking a history targeting evidence of heart failure, episodes of hypokalemia, a family history of long QT syndrome, or use of other medications known to prolong the QT interval and performed an ECG before starting treatment. This resulted in excluding 113 of 1,577 subjects (7.1%), 88 (5.6%) on the basis of history and 25 (1.6%) because of a prolonged QTc interval. We excluded another 10 subjects (0.8%) because they developed QTc prolongation on an ECG obtained 1 month after starting therapy (six [1.05%] were receiving azithromycin, and four [0.70%] were receiving placebo; P = 0.55). Using this approach, after 1 year of therapy we only encountered one cardiovascular death in each treatment group (0.18%), and all-cause mortality was 3.1% in subjects receiving azithromycin and 3.5% in those receiving placebo (P = 0.87) (88).

Although there are insufficient data available to know how much the above approach might decrease the incidence of macrolide-associated arrhythmias, the low cost and lack of risk associated with obtaining histories and ECGs suggest that it would be cost effective.

Macrolides can prolong the QT and QTc interval and cause cardiac arrhythmias, including TdP, ventricular tachycardia, and ventricular fibrillation, via their effect on the IKr potassium channel. Having conditions associated with QT prolongation or various other comorbidities increases the risk of developing arrhythmias in response to macrolides, perhaps by more than 24-fold (65). Studies documenting the RRs of subjects developing arrhythmias when taking macrolides compared with other classes of antibiotics or no antibiotics have reached conflicting conclusions (1, 64), perhaps because they examined different patient populations, but the study by Ray and colleagues (1) that reported increased RR of arrhythmias may have overestimated the RRs for the reasons discussed above.

The risk of arrhythmias in response to macrolides is related to the concentration of the medication in the blood and therefore to the dose, route, and rate of administration. Given the low concentrations resulting from oral dosing of macrolides, arrhythmias are unlikely to occur in the absence of additional issues that would reduce the “repolarization reserve.” Consistent with this concept is the estimate that the incidence of arrhythmias in response to macrolides in absence of additional risk factors is very low, perhaps < 1 in 100,000 subjects (65).

Regardless of what the RR and incidence of macrolide-associated arrhythmias might be, both can be reduced by not prescribing this class of medications to patients with comorbidities of concern, the majority of which can be discovered by taking a history, performing an ECG before initiating therapy, and repeating the ECG a short time thereafter.

The authors thank Drs. John Connett, Richard Casaburi, Jeffrey Curtis, Mark Dransfield, MeiLai Han, Barry Make, and Steve Sharf for making helpful suggestions on a previous draft of this work.

1. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:18811890.
2. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145172.
3. Straus SMJM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362367.
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:10131022.
5. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987;113:14701482.
6. Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:21202127.
7. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001;24:323351.
8. Arizona Center for Education and Research in Therapeutics. Drugs that prolong the QT interval and/or induce torsades de pointes [accessed 2013 Aug 19]. Available from:
9. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:18321844.
10. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995;91:30103016.
11. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996;28:18361848.
12. Itoh H, Sakaguchi T, Ding WG, Watanabe E, Watanabe I, Nishio Y, Makiyama T, Ohno S, Akao M, Higashi Y, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol 2009;2:511523.
13. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med 1989;111:549551.
14. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96:27782781.
15. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691696.
16. Paulussen ADC, Gilissen RAHJ, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJM, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004;82:182188.
17. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007;4:603607.
18. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105:19431948.
19. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529533.
20. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:16251633.
21. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327:846852.
22. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SAN. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175187.
23. Roden DM. Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:10291034.
24. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115172.
25. Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 1988;319:257262.
26. Ponsonnaille J, Citron B, Richard A, Trolese JF, Chaperon A, Barret B, Gras H. Electrophysiological study of pro-arrhythmogenic effects of erythromycin [in French]. Arch Mal Coeur Vaiss 1988;81:10011008.
27. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest 1999;115:983986.
28. Kdesh A, McPherson CA, Yaylali Y, Yasick D, Bradley K, Manthous CA. Effect of erythromycin on myocardial repolarization in patients with community-acquired pneumonia. South Med J 1999;92:11781182.
29. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89:235238.
30. Houin G, Tillement JP, Lhoste F, Rapin M, Soussy CJ, Duval J. Erythromycin pharmacokinetics in man. J Int Med Res 1980;8:914.
31. Austin KL, Mather LE, Philpot CR, McDonald PJ. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273279.
32. Nilsen OG. Comparative pharmacokinetics of macrolides. J Antimicrob Chemother 1987;20:8188.
33. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, Iga T. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother 2000;44:26302637.
34. Milberg P, Eckardt L, Bruns H-J, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218225.
35. McComb JM, Campbell NPS, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984;54:922923.
36. Gueugniaud PY, Guerin C, Mahul P, Deu C, Robert D. Torsade de pointes induced by the combination lidocaine-erythromycin and hepatic insufficiency [in French]. Presse Med 1985;14:896.
37. Guelon D, Bedock B, Chartier C, Haberer J-P. QT prolongation and recurrent “torsades de pointes” during erythromycin lactobionate infusion. Am J Cardiol 1986;58:666.
38. Freedman RA, Anderson KP, Green LS, Mason JW. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 1987;59:168169.
39. Kilani F, Marsepoil T. Attack of torsades de pointes induced by an intravenous injection of erythromycin lactobionate [in French]. Ann Fr Anesth Reanim 1988;7:270271.
40. Hummel JC, Haberer JP. Peroperative circulatory arrest after intravenous injection of erythromycin lactobionate [in French]. Ann Fr Anesth Reanim 1988;7:8586.
41. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ 1990;300:13751376.
42. Lindsay J Jr, Smith MA, Light JA. Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 1990;98:222223.
43. Benoit A, Bodiou C, Villain E, Bavoux F, Checoury A, Badoual J. QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant [in French]. Arch Fr Pediatr 1991;48:3941.
44. de Koning J, van der Hoeven H, Hamer B, Thompson J. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia. Neth J Med 1994;44:131135.
45. Rezkalla MA, Pochop C. Erythromycin induced Torsades de Pointes: case report and review of the literature. S D J Med 1994;47:161164.
46. Brandriss MW, Richardson WS, Barold SS. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin Infect Dis 1994;18:995998.
47. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996;16:663674.
48. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989;86:465466.
49. Vogt AW, Zollo RA. Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anesth Analg 1997;85:10111013.
50. Lee KL, Jim M-H, Tang SC, Tai Y-T. QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 1998;104:395396.
51. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999;22:672674.
52. Wasmer K, Hindricks G, Kottkamp H. Clarithromycin-assoziierte syncope als erstmanifestation eines angeborenen langen QT-syndromes? Intensivmed 1999;36:5344.
53. Kamochi H, Nii T, Eguchi K, Mori T, Yamamoto A, Shimoda K, Ibaraki K. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421422.
54. Hicks LA, Taylor TH Jr, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 2013;368:14611462.
55. Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000;23:14331435.
56. Arellano-Rodrigo E, García A, Mont L, Roqué M. Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome [in Spanish]. Med Clin (Barc) 2001;117:118119.
57. Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 2001;24:15721574.
58. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003;116:U666.
59. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006;77:3032.
60. Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 2005;28:12211222.
61. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007;18:243246.
62. Raschi E, Poluzzi E, Koci A, Moretti U, Sturkenboom M, De Ponti F. Macrolides and torsadogenic risk: emerging issues from the FDA pharmacovigilance database. J Pharmacovigilance 2013;1:104.
63. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med 2006;17:254259.
64. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:10891096.
65. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368:16651668.
66. Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21:301319.
67. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:25902597.
68. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:14711474.
69. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280:17741776.
70. Pham TV, Sosunov EA, Gainullin RZ, Danilo P Jr, Rosen MR. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 2001;103:22072212.
71. Pham TV, Sosunov EA, Anyukhovsky EP, Danilo P Jr, Rosen MR. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation 2002;106:21322136.
72. Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res 2002;53:763769.
73. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, Davignon A. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690695.
74. Lehmann MH, Hardy S, Archibald D, Quart B, McNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996;94:25342541
75. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368:17041712.
76. Albert RK. “Lies, damned lies ...” and observational studies in comparative effectiveness research. Am J Respir Crit Care Med 2013;187:11731177.
77. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, Hildebrandt P, Hilden J, Hensen GB, Kastrup J, et al.; the CLARICOR Trial Group. Randomized placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:2227.
78. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, Singanayagam A, Hill AT, Chalmers JD. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346:f1235.
79. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404407.
80. Anderson JL, Muhlesstein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Randomized secondary prevention trail of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumonia infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:15401547.
81. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS Study. Eur Heart J 1999;20:121127.
82. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS for the Clarithromycin in acute coronary syndrome patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002;105:15551560.
83. Stone AFM, Mendall MA, Kaski J-C, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106:12191223.
84. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, Gottwik M, Altmann E, Seidel F, Rox J, et al.; Working Group of Leading Hospital Cardiologists. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003;107:12531259.
85. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer PK; AZACS Investigators. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003;361:809813.
86. O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD; Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290:14591466.
87. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, Pokum S. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 2001;84:S669S675.
88. Berg HF, Maraha B, Scheffer G-J, Quarles-van Ufford M, Vandenbroucke-Grauls CM, Peeters MF, Kluytmans JA. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis 2005;40:358365.
89. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, et al.; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:16371645.
90. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689698.
Correspondence and requests for reprints should be addressed to Richard K. Albert, M.D, Denver Health, 660 Bannock, MC 4000, Denver, CO 80204-4507. E-mail:

Author Contributions: J.L.S. contributed to the first draft of the section on electrophysiology and genetics and reviewed and suggested revisions of the penultimate draft of the manuscript. R.K.A. wrote the first draft of the manuscript and revised the penultimate draft in response to input from a number of investigators listed in the acknowledgments.

CME will be available for this article at

Originally Published in Press as DOI: 10.1164/rccm.201402-0385CI on April 7, 2014

Author disclosures are available with the text of this article at


No related items
Comments Post a Comment

New User Registration

Not Yet Registered?
Benefits of Registration Include:
 •  A Unique User Profile that will allow you to manage your current subscriptions (including online access)
 •  The ability to create favorites lists down to the article level
 •  The ability to customize email alerts to receive specific notifications about the topics you care most about and special offers
American Journal of Respiratory and Critical Care Medicine

Click to see any corrections or updates and to confirm this is the authentic version of record